Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study-Reference-Cited by-同舟云学术

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Published:2016-07-13 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Kasi Pashtoon M.,Kotani Daisuke,Cecchini Michael,Shitara Kohei,Ohtsu Atsushi,Ramanathan Ramesh K.,Hochster Howard S.,Grothey Axel,Yoshino Takayuki

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2491-y.pdf

Reference13 articles.

1. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.

2. Yamashita F, Komoto I, Oka H, et al. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer Chemother Pharmacol. 2015;76(2):325–33.

3. Tanaka N, Sakamoto K, Okabe H, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32(6):2319–26.

4. ClinicalTrials.gov. Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer. 2016; https://clinicaltrials.gov/ct2/show/NCT02286492 . Accessed 15 June 2016.

5. Kotani D, Shitara K, Kawazoe A, et al. Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single Institution. Clin Colorectal Cancer. 2015 [Epub ahead of print]

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case–control comparative study;Frontiers in Immunology;2024-02-27

2. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review;The Oncologist;2024-02-16

3. Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment;Oncology in Clinical Practice;2024-02-05

4. Progress of Chinese and Western Medicine Research on Leukopenia after Chemotherapy for Breast Cancer;Advances in Clinical Medicine;2024

5. Risk factors and prognostic impact of severe neutropenia in the first cycle of trifluridine-tipiracil for metastatic colorectal cancer patients: A single-center retrospective study;2023-12-12